Sorafenib for FLT3+ AML – pro
Sorafenib (Nexavar,) has been approved for the treatment of metastatic renal cancer and advanced hepatocellular carcinoma. It inhibits the serine threonine kinase RAF-1, but also the FLT3-RTK and FLT3-ITD, suggesting that it may have a role in treating AML with FLT3 mutations. Sorafenib is a FLT3 tyrosine kinase inhibitor, and approximately 25 percent of patients with de novo AML have the FLT3 mutation. Sorafenib in a phase 1 clinical trial on 16
Read more